放疗联合抗VEGF抗体对肝癌移植瘤血管形成因子影响的实验观察  

Effect of radiation combined with anti-VEGF monoclonal antibody on angiogenic factors in human hepatocellular carcinoma xenografts

作　　者：郑青平[1] 陈龙华[2] 石玉生[2] 倪秉强[1] 

机构地区：[1]柳州市人民医院肿瘤科,广西柳州545001 [2]南方医科大学南方医院放疗科,广东广州510515

出　　处：《中华肿瘤防治杂志》2008年第24期1852-1855,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨放疗联合抗血管内皮生长因子(VEGF)抗体抑制肝癌移植瘤血管形成因子的抑制作用。方法:SMMC-7721人肝癌细胞种植于裸鼠右后肢皮下,成瘤动物随机分为5组,每组5只。抗VEGF抗体50μg腹腔注射,隔日1次,共6次。第4次给药后放疗,6MeV电子线,剂量率4Gy/min。给药结束后2周处死动物,免疫组化检测肿瘤标本VEGF、缺氧诱生因子1α(HIF-1α)和基质金属蛋白酶2(MMP-2),并检测凋亡指数。结果:肝癌移植瘤VEGF中至强阳性表达,HIF-1α也表达中至强阳性,MMP-2弱至中阳性表达。抗VEGF抗体与放疗结合抑制VEGF和HIF-1α表达(P=0.002,P=0.013),放疗或抗体对MMP-2表达的影响差异无统计学意义,P=0.339。放疗和抗VEGF抗体均能诱导肿瘤细胞凋亡,凋亡指数13.62±1.70和14.38±2.70,高于对照组5.18±0.85,P=0.000,放疗和抗VEGF抗体联合的凋亡指数高于单一治疗组,P=0.000。结论:放疗与抗VEGF抗体协同抑制肝癌移植瘤血管形成因子,放疗与抗血管形成剂联合应用是肝癌综合治疗的有效途径。OBJECTIVE: To investigate the inhibiting effects of radiotherapy combined with antiangiogenic agent on angiogenic factors in human hepatocellular carcinoma xenografts in vivo.METHODS: Human hepatocellular carcinoma(HCC) cell line SMMC-7721 was cultured and implanted in the rear right legs of nude mice.The mice bearing 5-mm xenografts were randomized into 5 groups,each with 5 mice.Anti-VEGF mAb was injected on alternate days for a total of 6 injections at a dosage of 50 μg/injection for one mouse.Single radi...

关 键 词：肝肿瘤/放射疗法 肝肿瘤 实验性/药物疗法 内皮生长因子/免疫学 

分 类 号：R735.7[医药卫生—肿瘤]